Usual Interstitial Pneumonia Pattern Interstitial Lung Disease Developed in a Patient with IgG4-related Chronic Sclerosing Sialadenitis

Hiroshi Yamamoto¹, Masamichi Komatsu¹, Kei Sonehara¹, Yuichi Ikuyama¹, Kazuhsa Urushihata¹, Kazunari Tateishi¹, Yoshiaki Kitaguchi¹, Atsuhiho Ushuiki¹, Shiho Asaka², Takeshi Uehara², Satoshi Kawakami³, Kentaro Mori⁴, Kazutoshi Hamanaka⁵, Kenichi Nishie⁶, Akira Hebisawa⁷ and Masayuki Hanaoka¹

Abstract:
A 69-year-old man was diagnosed with immunoglobulin (Ig) G4-related disease (IgG4-RD) at 62 years old. At that time, he had high serum IgG4 levels and bilateral submandibular gland swelling on CT; thus, a gland biopsy was performed. Because a reticular shadow was found on chest CT, a lung surgical biopsy was also performed. The specimens revealed usual interstitial pneumonia (UIP) pattern interstitial pneumonia with some IgG4-positive cells. The patient was subsequently followed up without treatment. His forced vital capacity and radiological findings progressively deteriorated, consistent with UIP pattern interstitial lung disease but different from a lung lesion of IgG4-RD.

Key words: immunoglobulin (Ig) G4, immunoglobulin (Ig) G4-related disease (IgG4-RD), progressive fibrosing, interstitial pneumonia, usual interstitial pneumonia (UIP)

(Intern Med 61: 2637-2642, 2022)
(DOI: 10.2169/internalmedicine.8937-21)

Introduction
Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a systemic disease characterized by tumefactive lesions with abundant IgG4-positive plasma cells and high serum IgG4 concentrations (1-4). In the respiratory lesions of IgG4-RD, four major categories [solid nodular type, round-shaped ground-glass opacity (GGO) type, alveolar interstitial type with honeycombing, and bronchovascular type] have been reported (5). We previously reported 18 patients with IgG4-related respiratory disease (IgG4-RRD), which is characterized by respiratory involvement of IgG4-RD, with extrathoracic manifestations of IgG4-RD (6). All 18 patients had a benign prognosis. Interestingly, none of the 18 patients showed alveolar interstitial type with honeycombing. Thus, we wondered if a lung manifestation of IgG4-RD, such as alveolar interstitial type with honeycombing, actually existed.

We herein report a patient already diagnosed with IgG4-RD of the submandibular glands who showed a reticular shadow on chest CT and who underwent a lung surgical biopsy.

Case Report
A 62-year-old man with few respiratory symptoms was referred by the otolaryngology department for the examina-
A left mandibular gland biopsy was performed, and the specimen showed chronic sialadenitis with a storiform pattern of fibrosis (Fig. 2a). An immunohistochemical examination of the specimen revealed increased infiltration of IgG4-positive plasma cells [IgG4-positive cells >10/high-power field (HPF) and IgG4-positive/IgG-positive cell ratio >40%] (Fig. 2b, c). Furthermore, reticular shadows of bilateral lungs were noted in a radiologist’s diagnostic report of the FDG-PET/CT findings.

At the first visit to our division, the patient was 145.2 cm tall and weighed 40.5 kg. His peripheral oxygen saturation (SpO₂) was 98%, and fine crackles were heard in his bilateral lower chest.

Laboratory examinations showed the following values, seen in a Table below (normal range): peripheral white blood cell count, 8,080/μL; hemoglobin (Hb), 12.9 g/dL;
Table. Laboratory Data and Pulmonary Function Tests on Admission.

| Laboratory Data | Pulmonary function tests (PFTs) | % predicted |
|-----------------|---------------------------------|-------------|
| WBC 8.800 /μL  | CRP 0.09 mg/dL                  | VC 2.10 L   | 73.7 %       |
| Net 78.2 %     | IgG 2,731 mg/dL                 | FVC 2.40 L  | 84.8 %       |
| Mon 8.9 %      | IgG1 (<1,080)                   | FEV1 2.12 L | 91.8 %       |
| Eos 0 %        | IgG2 (<931)                     | FEV1/FVC 88.3 % |
| Baso 0 %       | IgG3 (<121)                     | PEF 8.12 L/s | 116.7 %      |
| Lym 12.9 %     | IgG4 (<108)                     | D_LCO 13.66 mL/min/mmHg | 61.6 % |
| RBC 4.23×10^4 /μL | IgG4/IgG 35.3 % |                              |
| Hb 12.9 g/dL    | IgA 162 mg/dL                  | Arterial blood gas analysis |
| Ht 38.4 %      | IgM 39 mg/dL                    | pH 7.419 |
| Plt 2.31×10^4 /μL | IgE 80 IU/mL                | pCO₂ 37.6 Torr |
| TP 8.4 g/dL     | RF -                            | pO₂ 90.5 Torr |
| ALB 4.0 g/dL    | Anti-nuclear antibody -         | pHCO₃⁻ 23.3 mmol/L |
| UN 19.3 mg/dL   | C3 104 mg/dL                   | BE 0.1 mmol/L |
| Cre 0.80 mg/dL  | C4 29 mg/dL                    |                          |
| Na 139 mmol/L  | Ferritin (<280)                | 134.0 mg/mL |
| K 3.9 mmol/L   | PR3-ANCA - U/mL                |                          |
| Cl 109 mmol/L  | MPO-ANCA - U/mL                |                          |
| AST 38 IU/L     | KL-6 (<435)                    | 235 U/mL |
| ALT 51 IU/L     | sIL-2R (<421)                  | 759 U/mL |
| γ-GTP 166 IU/L  | ACE (<25)                      | 7.7 U/L |
| T-bil 0.59 mg/dL | IL-6 1.31 pg/mL               |                          |
| ALP 523 IU/L    | Urinalysis                      |                          |
| LDH (<230)     | PH 5.5                          |                          |
| PT 11.5 s      | SG 1.015                       |                          |
| APTT 28.4 s    | Protein -                      |                          |
| FIBG 333.0 mg/dL | Glucose -                    |                          |
|                | Occult blood -                  |                          |

sIL-2R: soluble interleukin-2 receptor, VC: vital capacity, ACE: angiotensin-converting enzyme, FVC: forced vital capacity, KL-6: Krebs von den Lungen-6, FEV1: forced expiratory volume in one second, PEF: peak expiratory flow, D_LCO: diffusing capacity of the lung for carbon monoxide

platelet (PLT), 23.1×10^4 /μL; total protein (TP), 8.4 g/dL; albumin, 4.0 g/dL; lactate dehydrogenase (LD), 162 IU/L (<220); C-reactive protein, 0.09 mg/dL; Krebs von den Lungen-6 (KL-6), 235 U/mL (<435); IgG, 2,731 mg/dL (<1,700); and IgG4, 966 mg/dL (<108). The serum autoantibodies were all negative. Pulmonary function tests (PFTs) revealed the following values, seen in a Table below: a vital capacity (VC) of 2.10 L (73.7% predicted), a forced vital capacity (FVC) of 2.40 L (84.8% predicted), and a diffusing capacity of the lung for carbon monoxide (D_LCO) of 13.66 mL/min/mmHg (61.6% predicted).

Chest X-ray showed a reticular shadow in the bilateral lower lung fields (Fig. 3a). Chest CT revealed bilateral ground-glass and reticular opacities predominantly in the lower and peripheral lung zones (Fig. 3b-d). We obtained surgical lung biopsy specimens of the left lung [segment (S) 4, S6, S8], which revealed chronic fibrosing interstitial pneumonia with a usual interstitial pneumonia (UIP) pattern (Fig. 4a) (7, 8). An immunohistochemical examination showed some IgG4-positive plasma cell infiltration (>10/HPF and IgG4-positive cells/IgG-positive cells >40%) surrounding the lymphoid follicle near the fibroblastic foci; however, neither obliterator vasculitis nor storiform fibrosis was observed, which are characteristic findings of IgG4-RD (Fig. 4b, c) (1-3). According to the proposed diagnostic criteria for IgG4-RRD (9), this case corresponded to “definite” IgG4-RRD. However, as the pathological findings of the patient showed UIP pattern interstitial pneumonia, we were unable to determine whether or not this lung lesion could be considered lung involvement of IgG4-RD or another interstitial disease that developed independently of IgG4-RD. The patient had few respiratory symptoms and had no desire for treatment; thus, we decided to follow the patient according to idiopathic pulmonary fibrosis (IPF) at that time. The patient was then carefully followed without treatment at another hospital. He became aware of mild shortness of breath, only during exertion. His PFT results showed changes over time; his FVC values at 65, 67, and 69 years of age were 2.23 L (75.9% predicted), 2.09 L (77.2% predicted), and 1.83 L (69.0% predicted), respectively. At 69 years old, chest X-ray and chest CT were performed. Chest X-ray showed the progression of the reticular shadow in the bilateral lower lung fields with reduced capacity (Fig. 5a). Chest CT revealed deteriorated bilateral ground-glass and reticular opacities, traction bronchiectasis, and honeycombing, predominantly in the lower and periph-
Figure 3. Chest X-ray at 62 years old showed reticular shadow in the bilateral lower lung fields (a). Chest CT at 62 years old revealed bilateral ground-glass and reticular opacities, predominantly in the lower and peripheral lung zones (b-d).

Figure 4. The surgical lung biopsy specimen showed chronic interstitial pneumonia with a usual interstitial pneumonia pattern [Hematoxylin and Eosin (H&E) staining, scale bar=1 mm] (a). An immunohistochemical examination of the specimen revealed a certain amount of IgG4-positive cell infiltration (>10/high-power field (HPF)) (arrows) surrounding the lymphoid follicle near the fibroblastic foci (arrowheads) [H&E staining (b) and IgG4 immunostaining (c), scale bar=50 μm].

eral lung zones (Fig. 5b-d). Due to the apparent deterioration of the radiological findings and FVC, the lung lesions were considered consistent with the clinical course of UIP pattern interstitial lung disease (ILD), such as IPF, and showed a progressive fibrosing phenotype (10).

Discussion

We reported an elderly man with IgG4-RD who was pathologically diagnosed with UIP pattern interstitial pneumonia with some IgG4-positive cell infiltration at 62 years old. After following the patient for seven years without medication, the patient showed a significant decrease in FVC along with a decline in his chest CT findings.

The patient was diagnosed with submandibular grands involvement of IgG4-RD based on the comprehensive diagnostic criteria for IgG4-RD (1). Because the patient had elevated serum IgG4 levels, an extrathoracic lesion of IgG4-RD, bilateral infiltrative shadow on chest CT, and some IgG4-positive plasma cell infiltration (>10/HPF and IgG4-positive cells/IgG-positive cells >40%) in the lung biopsy specimen, his lung lesion met the diagnostic criteria for IgG4-RRD (9). IgG4-RRD develops through the lymphatic routes with abundant IgG4-positive cells in the lungs and responds well to corticosteroid therapy with a benign prognosis (6, 11, 12). Because the UIP pattern interstitial pneumo-
nia of the patient did not show obliterative vasculitis and storiform fibrosis, which are characteristic findings of IgG4-RD, the pathological findings of the lung lesion were considered inconsistent with those of IgG4-RD developing through the lymphatic routes (6). Furthermore, the lung lesion of the patient deteriorated slowly but progressively, and honeycombing became apparent. This clinical course and the progression of the CT findings of this lung lesion were considered consistent with UIP pattern ILD (e.g. IPF) and differed from IgG4-RD (6).

Recently, we reported 16 patients with IgG4-positive interstitial pneumonia (IP) who showed abundant IgG4-positive cells in the lungs and elevated serum IgG4 levels without extrathoracic lesions of IgG4-RD (13). Histopathologically, marked numbers of IgG4-positive cells in the fibrous parenchyma were observed in 14 patients. However, none of these 16 patients had either obliterative vasculitis or storiform fibrosis. The characteristic chest CT findings of IgG4-positive IP, which differed somewhat from those of IgG4-RD, as we previously reported (6), were ground-glass opacities (n=16), reticular opacities (n=11), traction bronchiectasis (n=10), thickening of the interlobular septal wall (n=9), and hilar mediastinal lymphadenopathy (n=6). We detected a correlation between the distribution of ground-glass opacities on chest CT and the lymphoplasmacytic inflammation in the lung tissue. Furthermore, a correlation existed between the patterns of traction bronchiectasis and reticular opacities on chest CT and histopathological fibrosis. All 15 patients with ground-glass opacities on chest CT who received steroid treatment showed improvement. In contrast, the reticular opacities deteriorated after the initiation of treatment in 6 of the 15 patients. Despite various treatments, three patients died (two patients due to chronic respiratory failure and one due to an acute exacerbation). We speculate that the improvement in ground-glass opacities on chest CT reflected the elimination of IgG4-positive cell infiltration from the perilymphatic stromal area in the lung. Residual fibrosis may have been the essence of IP leading to progressive fibrosis, even though the ground-glass opacities improved with corticosteroid treatment. We conclude that IgG4-positive IP should be treated as a different category from conventional IgG4-RD because of the significant differences in disease behavior and responses to corticosteroid therapy.

The 2019 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for IgG4-RD were formulated from rheumatism-related academic societies (3). In the ACR/EULAR classification criteria, entry criteria, exclusion criteria, and inclusion criteria were clarified. In particular, poor responsiveness to corticosteroid therapy is emphasized in the exclusion criteria. Most patients with IgG4-positive IP are likely excluded from IgG4-RD by the ACR/EULAR classification criteria due to poor responsiveness to corticosteroid therapy. Furthermore, the 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD also state that the diagnosis should be reconsidered in cases of poor steroid responsiveness (14). Most patients with IgG4-positive IP are likely also excluded from IgG4-RD according to the 2020 RCD criteria for IgG4-RD.

The four types of lung lesions of IgG4-RD that were first reported (solid nodular, round-shaped GGO, alveolar inter-
stial with honeycombing, and bronchovascular type) were based on mainly radiological and pathological findings (5). By contrast, the clinical course, such as responsiveness to corticosteroid therapy, has been less thoroughly explored. Based on recent criteria for IgG4-RD (3, 14), we believe that it is essential to reassess the lung lesions of IgG4-RD, including their clinical course (e.g. treatment responsiveness). We therefore suggest that alveolar interstitial-type lung lesions with honeycombing, many of which fall under the definition of UIP pattern ILD and show a progressive fibrosing phenotype, do not fit the definition of IgG4-RRD with a benign prognosis. The lung lesion in our patient, who suffered from IgG4-RD of the submandibular glands, progressively deteriorated - a clinical course that was compatible with UIP pattern ILD, such as IPF, and which also indicated that it was less likely to be IgG4-RRD. The patient has not been receiving corticosteroid treatment according to IPF. Even if steroid treatment is performed in the future, it is highly possible that the reticular shadow will remain or deteriorate after the initiation of such treatment, as is the case with IgG4-positive IP. If the lung lesion of the patient was indeed lung involvement of IgG4-RD, the lesion might have been excluded from lung involvement of IgG4-RD based on the recent criteria. Thus, the lung lesion of the patient should be treated as a different category from conventional IgG4-RRD. We speculate that the patient’s lung lesion would have eventually more closely resembled UIP pattern ILD that developed independently of IgG4-RD than lung involvement of IgG4-RD. In the not-so-distant future, the use of anti-fibrotic drugs, such as nintedanib, may be considered for such cases.

In summary, the lung lesion of the patient with IgG4-related chronic sclerosing sialadenitis corresponded to definite according to the proposed diagnostic criteria for IgG4-RRD; however, the clinical course of this lung lesion was consistent with UIP pattern ILD, such as IPF, and differed from conventional IgG4-RRD. Thus, the lung lesion of our patient should be treated as a different category from IgG4-RRD, such as IgG4-positive IP. Our findings suggest that UIP pattern ILD may not be suitable for lung lesions of IgG4-RD. We propose excluding lung lesions with UIP pattern ILD, especially in cases presenting with the progressive fibrosing phenotype, from IgG4-RRD (9).

The authors state that they have no Conflict of Interest (COI).

Financial Support

This report was supported by the Ministry of Health, Labor and Welfare Research Program on Rare and Intractable Diseases (No. JPMH20FC1040), the Japan Society for the Promotion of Science (No.21K08175).

References

1. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22: 21-30, 2012.
2. Umehara H, Okazaki K, Kawa S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31: 529-533, 2021.
3. Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 79: 77-87, 2020.
4. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 366: 539-551, 2012.
5. Inoue D, Zen Y, Abe H, et al. Immunoglobulin G4-related lung disease: CT findings with pathologic correlations. Radiology 251: 260-270, 2009.
6. Matsui S, Hebisawa A, Sakai F, et al. Immunoglobulin G4-related lung disease: clinicoradiological and pathological features. Respiratory 18: 480-487, 2013.
7. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198: e44-e68, 2018.
8. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188: 733-748, 2013.
9. Matsui S, Yamamoto H, Minamoto S, et al. Proposed diagnostic criteria for IgG4-related respiratory disease. Respir Investig 54: 130-132, 2016.
10. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381: 1718-1727, 2019.
11. Sun X, Liu H, Feng R, et al. Biopsy-proven IgG4-related lung disease. BMC Pulm Med 16: 20, 2016.
12. Kang J, Park S, Chae EJ, et al. Long-term clinical course and outcomes of immunoglobulin G4-related lung disease. Respir Res 21: 273, 2020.
13. Komatsu M, Yamamoto H, Matsui S, et al. Clinical characteristics of immunoglobulin G4-positive interstitial pneumonia. ERJ Open Res 7: 00317-2021, 2021.
14. Umehara H, Okazaki K, Kawa S, et al. Research program for intractable disease by the Ministry of Health, Labor and Welfare (MHLW) Japan. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 31: 529-533, 2021.